Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Kitchener, H.C.

Refine Results

Resource Type

Availability

Creation Date

Show more

Language

Search results

  • RSS Feed
(1 - 20 of 21)

Pages

Radiation therapy techniques and treatment-related toxicity in the PORTEC-3 trial
Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial
Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3)
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative
Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
RELATION BETWEEN PATIENT AND PHYSICIAN REPORTED TOXICITY IN THE RANDOMISED PORTEC-3 TRIAL OF RADIATION THERAPY (RT) WITH OR WITHOUT CHEMOTHERAPY FOR ENDOMETRIAL CANCER
Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial
USE OF MOLECULAR MARKERS IMPROVES PROGNOSTIC STRATIFICATION IN HIGH RISK ENDOMETRIAL CANCER: A TRANSPORTEC COLLABORATIVE STUDY
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting Taking Endometrial Cancer Trials Into the Translational Era
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era

Pages